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LETTERS TO THE EDITOR
Changes in the composition of
carnitines in hemodialysis
patients
To the Editor: In their recent article, Evans et al [1]
demonstrated the temporal changes in the level and com-
position of carnitines before and after the commence-
ment of hemodialysis (HD) in their patients. The author
reported the percentage of plasma non-acetyl acyl carni-
tine increases with a longer duration of HD. The reason
for the change in composition, however, is less discussed.
We would like to put forward some explanations. Three
major enzymes play roles in the transportation of car-
nitine in mitochondria: carnitine palmitoyltransferase I
(CPT-I), carnitine/acylcarnitine translocase (CAT), and
carnitine palmitoyltransferase II (CPT-II). The fatty acid
is activated as acyl-CoA by acyl-CoA synthetase at the
outer mitochondria membrane. Acyl-CoA is then con-
verted to acylcarnitine by the CPT-I between the outer
and inner mitochondira membranes. Acylcarnitine, next,
is transported across the mitochondrial inner membrane
by a CAT. In mitochodria, acylcarnitine acts as a sub-
strate for CPT-II, transferring the acyl group to CoA
and releasing carnitine. Acyl CoA then enters the fatty
acid b-oxidation pathway [2]. If the activity of CAT or
CPT-II decreases, the acylcarnitine will then accumulate
and its plasma level will increase. Recent studies [3] have
demonstrated marked increase in the ratio of acyl to L-
carnitine in primary carnitine disorders (CAT or CPT-II
deficiency). Besides, Soejima et al [4] has reported a case
of partial CPT deficiency presenting with a higher acyl-
to-free carnitine ratio.
The recently discovered organic cation transporter
(OCTN2) plays a role in the reabsorption of carnitine
and short-chain acyl carnitine in kidneys [5]. This novel
transporter may decrease its preference for free carni-
tine in patients before dialysis. Thus, we suggested the
increase in the ratio of acyl/free carnitine in HD patients
may possibly result from loss of the preferential excre-
tion of acyl-carnitine by OCTN2, as well as decrease in
the activity of CAT or CPT-I.
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Reply from the Authors
We would like to thank the authors for their comments
regarding our recently published paper [1]. While we rec-
ognize that alterations in the enzymatic activity of CAT,
CPT, and OCTN2 may account, at least in part, for the
accumulation of acylcarnitines in chronic hemodialysis
patients, recent research by our group has suggested an
alternative cause for the changes in carnitine pool com-
position in this population.
A number of studies have investigated the impact of
a single hemodialysis session on acylcarnitine levels in
hemodialysis patients [2, 3]. These studies demonstrated
a significantly higher acylcarnitine to L-carnitine ratio in
postdialysis plasma samples compared to predialysis lev-
els, indicating a larger loss of L-carnitine than acylcar-
nitines into the dialysate.
A recent study by our group investigated the impact
of a dialysis session on individual endogenous acylcarni-
tine levels in chronic hemodialysis patients [4]. The study
examined pre- and postdialysis plasma concentrations of
L-carnitine and 31 individual acylcarnitines in 50 patients.
We demonstrated that 29 out of the 31 acylcarnitines were
significantly elevated in the ESRD population when com-
pared to healthy controls. For carnitine esters with an
acyl-chain length less than 8 carbons, plasma acylcarnitine
levels decreased significantly over the course of the dial-
ysis session; however, levels invariably remained higher
than those observed in the healthy population. Once acyl-
carnitine carbon-chain length exceeded 8 carbons, the di-
alytic removal of these compounds diminished, with a
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Fig. 1. Relationship between mean (± SEM) ratio of postdialysis/predialysis acylcarnitine concentrations and carbon-chain length of the acyl
group.
significant correlation between carbon-chain length and
dialytic removal (Fig. 1).
In light of these findings, we propose that, in combina-
tion with disturbed metabolism, the observed alterations
in the carnitine pool are contributed to by a decrease in
the dialytic removal of acylcarnitines, in particular long-
chain acylcarnitines, most likely a result of the increased
molecular weight and lipophilicity that accompanies in-
creased chain length.
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Albuminuria in patients with
hepatitis C: Is inflammation
the missing link?
To the Editor: The study by Liangpunsakul and Cha-
lasani on the association between hepatitis C and microal-
buminuria reports an independent association between
these 2 clinical entities [1]. The significance of their results
may, however, be limited by the fact that their use of 1
albumin to creatinine ratio to measure microalbuminuria
may be a source of error, including an underestimation
of microalbuminuria in some some racial/ethnic groups
[2].
Futhermore, their failure to find an association be-
tween hepatits C and the metabolic syndrome, may be
explained by the fact that in at least in some age groups,
